Post

MRD endpoint expected to usher new era for MM therapies

Last month, the Oncologic Drugs Advisory Committee (ODAC) for the US Food and Drug Administration (FDA) voted in favour of …

Edgewood Oncology treats first two subjects in breast cancer trial

Edgewood Oncology has treated the first two subjects in the Phase IIa clinical trial of BTX-A51, targeting patients with metastatic …

Vedanta Biosciences doses first subject in Phase III C difficile prevention trial

Vedanta Biosciences has dosed the first subject in Phase III RESTORATiVE303 clinical trial of VE303, a live biotherapeutic product candidate …

AiM Medical Robotics partners with Harvard Hospital for DBS study

AiM Medical Robotics has partnered with Harvard Medical School’s affiliate Brigham and Women's Hospital (BWH) to conduct a study validating …

J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trial

Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara (ustekinumab) medication in all endoscopic endpoints in a Phase II/III …